ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 576

Monitoring Of Opportunistic Virus Infections In Systemic Lupus Erythematosus

Lorenzo Cavagna1, Sandra Calarota2, Eva Scorletti3, Roberto Caporali4, Francesca Rovida5, Carlomaurizio Montecucco1 and Fausto Baldanti5, 1Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, 2Molecular Virology Unit, Virology and Microbiology Department, IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, 3Division of Rheumatology, University and IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, 4Division of Rheumatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy, 5Molecular Virology Unit, Virology and Microbiology Department, IRCCS Foundation Policlinico S. Matteo,, Pavia, Italy

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: opportunistic infections, systemic lupus erythematosus (SLE) and viruses

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects I - Renal, Malignancy, Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: due to disease characteristics and treatment approaches, systemic lupus erythematosus (SLE) patients are at high risk of opportunistic virus infections, as for example Epstein Barr virus (EBV) and human cytomegalovirus (hCMV). These viruses may complicate disease course, mimic SLE manifestations and have also been involved in SLE pathogenesis. An integrated clinical, virological and immunological monitoring may allow early diagnosis, characterization and right treatment of SLE patients. Aim of our study is to analyze the prevalence of both EBV and hCMV opportunistic infections in SLE and their relationship with disease characteristics/activity

Methods: from 2/15/2013, after ethical committee approval and informed consent collection, adults SLE patients (1997 ACR classification criteria) referring consecutively to our Lupus Unit have been enrolled in this study. Quantification of EBV DNA and CMV DNA in blood was performed by real-time PCR. Detailed information regarding demographic characteristics and clinical data  (disease duration, SLEDAI 2k score, occurrence of kidney involvement, etc) were obtained from the patients’ medical records. Patients were stratified according to the degree of pharmacological immunosuppression (Group 1= hydroxychloroquine and/or prednisone≤5 mg/day; group 2= methotrexate/azathioprine/cyclosporine and/or prednisone>5 and <12.5 mg/day; group 3= mycophenolate mofetil/rituximab and/or prednisone≥12.5 mg/day)

Results: a total of 64 SLE patients (59 females/5 males) have been analyzed (table 1). Group 1 consisted of 20 patients,  group 2 of 19 patients and group 3 of 25 patients. Although no patients were suspected for viral infection, 27 (42.2%) patients had detectable DNA either of EBV (n=24) or hCMV (n=1) or both (n=2). Viral load was generally low. Patients’ age, disease duration, SLEDAI 2k score and kidney involvement did not significantly influenced viral DNA load. In group 2, detection of viral DNA was significantly higher than group 3 (p=0.0136), while no differences were observed between group 1 and 2 (p=0.3406) and group 1 and 3 (p=0.2047). Group 2 patients with detectable virus DNA (n=12) were mainly on methotrexate (n=8) and cyclosporine (n=3)

Conclusion: in our patients  a high prevalence of EBV DNA and, to a lesser extent, hCMV DNA in blood has been observed. Detection of viral DNA is not related to disease and patients characteristics. However, patients treated with methotrexate and cyclosporine (group 2), were more prone to have viral DNA load with respect to patients treated with mycophenolate mofetil, rituximab or high dose corticosteroids.  Our results suggest suggested the need of a careful monitoring of SLE patients for the increased risk of EBV and hCMV infections. Analyses to better understand how virus-specific immune responses relate to opportunistic viral infections in SLE patients are ongoing

Virus DNA +ve (blood)

Virus DNA –ve (blood)

p

Patients number

27

37

EBV DNA +

24

hCMV DNA +

1

EBV and hCMV DNA +

2

EBV DNA (copies/ml; median -IQR)

196 (115-478)

CMV DNA (copies/ml; median -IQR)

200 (150-600)

Age (years; mediana – IQR)

56 (41.5-59.5)

44 (33-52)

0.0666*

Disease duration (months; median – IQR)

118 (75-152)

84 (6-154)

0.5278*

SLEDAI-2K score (median –IQR)

2 (2-4)

2 (2-4)

0.9967*

Kidney involvement (history)

6

15

0.1893µ

Group 1 (low level immunosuppression)

9

11

0.3406 (vs group 2) µ

Group 2 (medium level immunosuppression)

12

7

0.0136 (vs group 3)µ

Group 3 (high level immunosuppression)

6

19

0.2047 (vs group 1)µ

Table 1: main characteristics of patients up to now enrolled,

* independent sample T test, µ Fisher’s exact test.


Disclosure:

L. Cavagna,
None;

S. Calarota,
None;

E. Scorletti,
None;

R. Caporali,
None;

F. Rovida,
None;

C. Montecucco,
None;

F. Baldanti,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/monitoring-of-opportunistic-virus-infections-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology